Discovering the Innovation at UWC's SensorLab
The University of the Western Cape (UWC), a leading institution in South Africa's higher education landscape, has once again demonstrated its commitment to addressing national health challenges through cutting-edge research. At the heart of this breakthrough is SensorLab, a nanotechnology research hub founded in 2002 by Professor Emmanuel Iwuoha in the Department of Chemistry. Over the past two decades, SensorLab has trained more than 100 PhD graduates and pioneered low-cost sensors for diseases like HIV and TB, as well as environmental pollutants. This lab's latest achievement—a portable electrochemical biosensor—promises to revolutionize early screening for cancer, tuberculosis (TB), and long COVID, making diagnostics accessible even in remote South African clinics.
This innovation emerges from years of dedicated work, aligning with UWC's mission to foster research that tackles real-world problems. By leveraging nanotechnology, the team has created a device that requires no sophisticated laboratory infrastructure, a critical factor in a country where healthcare resources are often stretched thin.
How the Electrochemical Biosensor Works: A Step-by-Step Breakdown
An electrochemical biosensor is a compact device that detects biological molecules through electrical signals generated by chemical reactions. Unlike traditional lab tests, this UWC-developed sensor uses nanotechnology to functionalize electrodes with nanobodies or aptamers—tiny synthetic antibodies—that specifically bind to disease biomarkers in a blood sample.
- Sample Collection: A small drop of blood is applied directly to the sensor strip, eliminating the need for processing.
- Binding Phase: Biomarkers attach to the sensor surface, triggering an electrochemical reaction.
- Signal Generation: The reaction produces an electrochemiluminescent signal—a light-based electrical output—proportional to biomarker concentration.
- Readout: A portable reader delivers results in under 60 seconds, comparable to a pregnancy test but far more advanced.
This process ensures high reproducibility, even in human serum, with sensitivity down to 0.04 picograms per milliliter (pg/mL) for key markers. It's stable, reliable, and designed for point-of-care use, empowering community health workers without specialized training.
Targeting Critical Biomarkers for Cancer, TB, and Long COVID
The biosensor's versatility lies in its ability to detect multiple biomarkers from one sample, addressing South Africa's dual burden of infectious and non-communicable diseases.
- Cancer - Macrophage Capping Protein (CapG): Overproduced in aggressive cancers like breast, ovarian, and gastric. Early detection via CapG can signal tumor progression at picogram levels, where traditional biopsies often fail.
- Tuberculosis (TB) - Interferon Gamma (IFN-γ): An immune marker indicating active TB infection. TB, caused by Mycobacterium tuberculosis bacteria, remains South Africa's leading cause of death, with 270,000 people living with it and 56,000 deaths in 2023 alone.
- Long COVID - SARS-CoV-2 Spike Protein: Detects persistent viral reservoirs post-infection, linked to symptoms like chronic fatigue and brain fog. With estimates of 500,000 long COVID cases in South Africa, this could identify at-risk individuals early.
The technology builds on a study published in the peer-reviewed journal Bioelectrochemistry, validating its high sensitivity for spike protein detection.
Overcoming Limitations of Traditional Diagnostics
Current methods like polymerase chain reaction (PCR) for TB or biopsies for cancer are costly and inaccessible. In South Africa, PCR tests can cost $15-25 per run, while biopsies range from thousands of Rand, often requiring urban hospitals.
| Method | Cost | Time | Location |
|---|---|---|---|
| UWC Biosensor | $1-5 | <60 seconds | Clinic/Field |
| PCR (TB) | $15-25 | Hours-Days | Lab |
| Biopsy (Cancer) | Thousands Rand | Weeks | Hospital |
The UWC test slashes these barriers, potentially cutting TB transmission by 50% through early detection and boosting cancer survival rates by 30-90%.
Photo by National Cancer Institute on Unsplash
South Africa's Disease Burden and the Test's Potential Impact
South Africa faces a staggering health crisis: TB claims 56,000 lives yearly, cancer cases are projected to double to 120,000 annually by 2030, and long COVID affects up to 500,000, straining post-pandemic recovery. Rural and underserved communities suffer most, with late diagnoses leading to higher mortality.
This biosensor supports the National Health Insurance (NHI) by enabling widespread screening, reducing hospitalizations, and promoting equity. For instance, in high-TB areas like KwaZulu-Natal, rapid IFN-γ detection could interrupt transmission chains swiftly.
Read the full UWC announcement for more details.
Spotlight on Dr. Jaymi Leigh January: The Lead Innovator
Dr. Jaymi Leigh January, a December 2025 PhD graduate and DSTI–Dr Ivy Matsepe-Casaburri Fellow, led this research. "This addresses an urgent South African health challenge—the need for accessible diagnostics in a country with disproportionate disease burdens," she stated.
Supervised by Prof. Iwuoha, with collaborators from UWC's Dr. Nelia Sanga and Belgium's University of Ghent, her work exemplifies interdisciplinary excellence. Aspiring researchers can find inspiration—and opportunities—in UWC's programs. Check out research jobs or research assistant positions to contribute to similar innovations.
Broader Implications for Higher Education and Research in South Africa
UWC's feat underscores the role of South African universities in global health solutions. SensorLab's track record positions UWC as a nanotechnology leader, attracting funding and talent. This could spur more investments in STEM higher education, creating jobs in biosensor development and clinical trials.
For academics and students, it highlights career paths in applied research. Explore tips for academic CVs or lecturer jobs in South Africa via AcademicJobs South Africa.
Learn about the publication in Bioelectrochemistry.
Future Outlook: Scaling Up and Global Reach
Next steps include clinical trials, smartphone integration, and WHO partnerships for deployment by 2028. Regulatory approval could make it standard in SA clinics, expandable to other diseases like HIV.
This innovation not only saves lives but elevates UWC's global standing, encouraging more youth into science. Interested in higher ed careers? Visit higher ed jobs, university jobs, and career advice.
Why This Matters for Researchers and Healthcare Professionals
For those in academia, this showcases the impact of persistent research amid challenges. Dr. January's journey—from PhD hurdles to publication—offers lessons in resilience. South African universities like UWC are hubs for such transformative work, fostering the next generation of innovators.
Stakeholders, including government and NGOs, see this as a model for sustainable health tech. As SA pushes NHI, tools like this ensure equitable access.